- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Vital Chemtech's Q4 FY26 EBITDA rose 39.7% to ₹4.0 Cr. Full-year PAT declined to ₹1.0 Cr, impacted by investments in subsidiaries Vital Synthesis (now operational) and Vital Alkoxides (63% revenue growth). Focus is on long-term specialty chemical expansion.